University of Sri Jayewardenepura, Nugegoda, Sri Lanka,
National Hospital Sri Lanka, Colombo 10, Sri Lanka.
Ceylon Med J. 2021 Dec 31;66(4):177-184. doi: 10.4038/cmj.v66i4.9508.
The acceptability of a vaccine is an important factor during mass vaccination programs and this is largely dependent on the symptoms of local and systemic reactogenicity. There is paucity of data on the systemic and local reactions experienced by COVD-19 vaccine recipients in South Asia.
To identify the early local and systemic reactogenicity of ChAdOx1 nCoV-19 vaccine.
A multicenter observational study was performed to identify the reactogenicity to ChAdOx1 nCoV-19 vaccine in healthcare workers following the first dose.
There were 4478 participants with a median age of 42 years (IQR 34-51) and 2863 (63.9%) were females. At least one symptom of reactogenicity was reported by 4151 (92.7%). Local reactions were reported by 2612 (58.3%). Systemic reactions were bodyache (3244,72.4%), fatigue (2379, 53.1%), headache (2277, 50.8%), fever (2290, 51.1%), feverishness (1912, 42.7%) and chills (2295, 51.3%). Lower age (p<0.0001) and female gender (p 0.002) were associated with a higher frequency of developing systemic reactions. There was no association between reactogenicity and comorbidities. There were 342 (7.6%) reports of palpitations and one case of ventricular bigeminy. There was one report of anaphylaxis and hospital admissions were reported by 24 (0.5%). One vaccine recipient was managed for possible aseptic meningitis.
This study demonstrates that early systemic and local reactions are common. Systemic reactions were more frequent in females and in the younger population. Most symptoms were self- limiting and did not require medical attention or hospital admission. ChAdOx1 nCoV-19 vaccine appears safe in the studied population.
疫苗的可接受性是大规模疫苗接种计划中的一个重要因素,这在很大程度上取决于局部和全身不良反应的症状。关于南亚 COVID-19 疫苗接种者经历的全身和局部反应的数据很少。
确定 ChAdOx1 nCoV-19 疫苗的早期局部和全身不良反应。
进行了一项多中心观察性研究,以确定首剂 ChAdOx1 nCoV-19 疫苗在医护人员中的全身和局部不良反应。
共有 4478 名参与者,中位年龄为 42 岁(IQR 34-51),2863 名(63.9%)为女性。至少有一种不良反应症状的报告有 4151 名(92.7%)。局部反应的报告有 2612 名(58.3%)。全身反应为肌肉疼痛(3244,72.4%)、疲劳(2379,53.1%)、头痛(2277,50.8%)、发热(2290,51.1%)、发热(1912,42.7%)和寒战(2295,51.3%)。年龄较小(p<0.0001)和女性(p<0.002)与全身反应的发生频率更高相关。不良反应与合并症之间没有关联。有 342 例(7.6%)报告心动过速,1 例报告室性二联律。有 1 例过敏反应报告,24 例(0.5%)报告住院。1 例疫苗接种者被诊断为可能的无菌性脑膜炎。
本研究表明,早期全身和局部反应很常见。女性和年轻人群中全身反应更为常见。大多数症状是自限性的,不需要医疗关注或住院治疗。在研究人群中,ChAdOx1 nCoV-19 疫苗似乎是安全的。